Abstract
Hepatitis C virus infection is a common cause of chronic liver disease and hepatocellular carcinoma. Recently, mutations in the p53 tumor suppressor gene with generation of circulating autoantibodies to p53 protein have been detected in a significant proportion of patients with different malignancies. Using ELISA methods we assessed α-fetoprotein and anti-p53 as serological screening parameters for hepatocellular carcinoma in 147 consecutive patients with chronic hepatitis C. Liver cirrhosis was histologically diagnosed in 58 patients (39.5%) and a hepatocellular carcinoma confirmed in seven patients (4.8%). Serum α-fetoprotein was raised above 20 ng/ml in 26/147 patients and above 100 ng/ml in 5/147 patients. In 6/7 patients with hepatocellular carcinoma, α-fetoprotein was raised above 20 ng/ml, but only in 3/7 cases above 100 ng/ml, resulting in a sensitivity and specificity of 85.7% and 85.7% (α-fetoprotein>20 ng/ml) and 42.9% and 98.6% (α-fetoprotein>100 ng/ml), for the detection of hepatocellular carcinoma, respectively. Autoantibodies to p53 were detected in 3/7 patients with hepatocellular carcinoma, but in 0/140 patients without malignancy (sensitivity 42.9%, specificity 100%). Screening for hepatocellular carcinoma was improved by combining α-fetoprotein measurement (level>100 ng/ml) with detection for anti-p53 (sensitivity 71.4%, specificity 98.6%). In conclusion, the presence of anti-p53 was highly specific for malignancy and independent of α-fetoprotein status. Further studies including a larger number of patients with hepatitis C virus-related hepatocellular carcinoma are required to investigate whether serological testing for anti-p53 in combination with α-fetoprotein might improve the detection of hepatocellular carcinoma in high-risk patients with liver cirrhosis.
Similar content being viewed by others
References
Kurstak E: Hepatitis C and hepatitis E viruses: Epidemiology and transmission.In Viral Hepatitis. Current Status and Issues. E Kurstak (ed). Wien, Springer-Verlag, 1993, pp 181–184
Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47–53, 1993
Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, Idrovo V, Rabassa A, Schiff ER: Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18:1326–1333, 1993
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801, 1993
Imberti D, Fornari F, Sbolli G, Buscarini E, Squassante L, Buscarini L: Hepatocellular carcinoma in liver cirrhosis. A prospective study. Scand J Gastroenterol 28:540–544, 1993
Bruix J, Calvet X, Costa J, Ventura M, Bruguera M, Castillo R, Barrera JM, Ercilla G, Sanchez-Tapias JM, Vall M, Bru C, Rodes J: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 28:1004–1006, 1989
Colombo M, Rumi MG, Donato MF, Tommasini MA, Del Ninno E, Ronchi G, Kuo G, Houghton M: Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. Dig Dis Sci 36: 1130–1133, 1991
Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ: The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 69:342–345, 1992
Tanaka K, Hirohata T, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Nawata H, Ishibashi H, Maeda Y, Kiyokawa H, Tokunaga K, Irita Y, Takeshita S, Arase Y, Nishino N: Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 51:2842–2847, 1991
Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325:675–680, 1991
Munoz N, Bosch FX: Epidemiology of hepatocellular carcinoma.In Neoplasms of the Liver. K Okuda, KG Ishak (eds). Tokyo, Springer-Verlag, 1987, pp 3–19
Cottone M, Turri M, Caltagirone M, Maringhini A, Sciarrino E, Virdone R, Fusco G, Orlando A, Marino L, Pagliaro L: Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and α-fetoprotein: A prospective study. Hepatogastroenterology 35:101–103, 1988
Okuda K: Early recognition of hepatocellular carcinoma. Hepatology 6:729–738, 1986
Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H: Imaging diagnosis of small hepatocellular carcinoma. Hepatology 20:82–87, 1994
Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19:61–66, 1994
Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S: Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 328:1802–1806, 1993
Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318–1327, 1993
Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49–53, 1991
Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453–456, 1991
Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K: Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 53:2884–2887, 1993
Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54:231–235, 1994
Volkmann M, Hofmann WJ, Müller M, Räth U, Otto G, Zentgraf H, Galle PR: p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 9:195–204, 1994
Collier JD, Carpenter M, Burt AD, Bassendine MF: Expression of mutant p53 protein in hepatocellular carcinoma. Gut 35:98–100, 1994
Laurent-Puig P, Flejou JF, Fabre M, Bedossa P, Belghiti J, Gayral F, Franco D: Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma. Hepatology 16:1171–1175, 1992
Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May E, Debuire B: p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 108:1176–1182, 1995
Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403–408, 1982
Legros Y, Meyer A, Ory K, Soussi T: Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 9:3689–3694, 1994
Volkmann M, Müller M, Hofmann WJ, Meyer M, Hagelstein J, Räth U, Kommerell B, Zentgraf H, Galle PR: The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 18:559–565, 1993
Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168–4174, 1992
Bukh J, Purcell RH, Miller RH: Importance of primer selection for the detection of hepatitis C virus RNA with polymerase chain reaction assay. Proc Natl Acad Sci USA 89:187–189, 1992
Zeuzem S, Rüster B, Roth WK: Clinical evaluation of a new polymerase chain reaction assay (AmplicorTM HCV) for detection of hepatitis C virus. Z Gastroenterol 32:342–347, 1994
Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Cancer 64:1700–1707, 1989
Kondo F, Wada K, Nagato Y, Nakajima T, Kondo Y, Hirooka N, Ebara M, Ohto M, Okuda K: Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9:751–755, 1989
Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS, Hsu HC: Expression and hypomethylation of α-fetoprotein gene in unicentric and multicentric human hepatocellular carcinoma. Hepatology 17:35–41, 1993
Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen FM, Hino O, Smith M, McMahon BJ, Lanier AP, London WT, Redeker AG, Govindarajan S: Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA 89:9622–9626, 1992
Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancer. Proc Natl Acad Sci USA 89:3439–3442, 1992
Labrecque S, Naor N, Thomson D, Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468–3471, 1993
Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264:1317–1319, 1994
Unsal H, Yakicier C, Marçais C, Kew M, Volkmann M, Zentgraf H, Isselbacher KJ, Ozturk M: Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 91:822–826, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Readle, J., Roth, W.K., Oremek, G. et al. α-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Digest Dis Sci 40, 2587–2594 (1995). https://doi.org/10.1007/BF02220446
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02220446